Biovica International AB (BIOVIC B) NPV B

Sell:2.05 SEKBuy:2.11 SEK0.19 SEK (8.30%)

Prices delayed by at least 15 minutes
Sell:2.05 SEK
Buy:2.11 SEK
Change:0.19 SEK (8.30%)
Prices delayed by at least 15 minutes
Sell:2.05 SEK
Buy:2.11 SEK
Change:0.19 SEK (8.30%)
Prices delayed by at least 15 minutes

Company Information

About this company

Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

Key people

Anders Rylander
Chief Executive Officer, Director
Anders Moren
Chief Financial Officer
Henrik Winther
Senior Vice President - Business Development
Helle Fisker
Vice President - Commercial and Marketing
Hanna Ritzen
Vice President - Research & Development
Hector Tamburini
Head of US Laboratory Operations, Regulatory & Quality
Lars Holmqvist
Independent Chairman of the Board
Annika Carlsson Berg
Independent Director
Marielouise Fjallskog
Independent Director
Maria Birgitte Holmlund
Independent Director
Jarl Ulf Jungnelius
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Sweden
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    SE0008613731
  • Market cap
    SEK 192.53m
  • Employees
    27
  • Shares in issue
    91.52m
  • Exchange
    Stockholm Stock Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.